biostudies-literatureUnknown17(3)Kaneko S<h4>Background</h4>Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA-II is unclear. This prospective study aimed to verify Elecsys PIVKA-II compared with Lumipulse PIVKA-II in a cohort with advanced HCC undergoing systemic therapy.<h4>Methods</h4>A total of 62 HCC patients who were treated with atezolizumab and bevacizumab (ATZ+BEV) and molecular targeted agents (MTAs) were prospectively enrolled at Musashino Red Cross Hospital from January 2020 to December 2020. A total of 208 serum samples from 52 patients were tested using Elecsys PIVKA-II and Lumipulse PIVKA-II assays. Furthermore, the relationshPloS onee0265235https://www.ebi.ac.uk/biostudies/studies/S-EPMC8912231biostudies-literatureClinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.PMC8912231Tsuchiya KTakaura KYasui YKirino SNobusawa TInada KHiguchi MMaeyashiki CTamaki NKurosaki MKaneko STakahashi YTanaka YTanaka SMatsumoto HNakanishi HIzumi NIshido SYamashita KKakegawa THayakawa YfalseClinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.<h4>Background</h4>Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA-II is unclear. This prospective study aimed to verify Elecsys PIVKA-II compared with Lumipulse PIVKA-II in a cohort with advanced HCC undergoing systemic therapy.<h4>Methods</h4>A total of 62 HCC patients who were treated with atezolizumab and bevacizumab (ATZ+BEV) and molecular targeted agents (MTAs) were prospectively enrolled at Musashino Red Cross Hospital from January 2020 to December 2020. A total of 208 serum samples from 52 patients were tested using Elecsys PIVKA-II and Lumipulse PIVKA-II assays. Furthermore, the relationsh2022-01-01T00:00:00Z20222025-04-19T00:39:16.314Z2025-04-07T11:43:33.766ZS-EPMC89122313527167010.1371/journal.pone.0265235